S&P 500   4,449.73 (+0.02%)
DOW   34,768.32 (+0.01%)
QQQ   371.17 (-0.49%)
AAPL   146.06 (-0.52%)
MSFT   297.29 (-0.76%)
FB   348.59 (+0.76%)
GOOGL   2,832.87 (+0.30%)
TSLA   761.30 (+1.02%)
AMZN   3,399.44 (-0.48%)
NVDA   218.98 (-2.60%)
BABA   146.34 (-3.21%)
NIO   35.51 (-1.39%)
CGC   13.98 (-3.98%)
GE   104.00 (+1.01%)
MU   74.30 (+0.35%)
AMD   105.12 (-0.97%)
T   27.17 (-0.07%)
F   13.84 (+0.95%)
ACB   6.01 (-2.28%)
DIS   175.56 (-0.39%)
PFE   43.93 (-0.59%)
BA   221.16 (+0.03%)
BAC   42.22 (+1.27%)
S&P 500   4,449.73 (+0.02%)
DOW   34,768.32 (+0.01%)
QQQ   371.17 (-0.49%)
AAPL   146.06 (-0.52%)
MSFT   297.29 (-0.76%)
FB   348.59 (+0.76%)
GOOGL   2,832.87 (+0.30%)
TSLA   761.30 (+1.02%)
AMZN   3,399.44 (-0.48%)
NVDA   218.98 (-2.60%)
BABA   146.34 (-3.21%)
NIO   35.51 (-1.39%)
CGC   13.98 (-3.98%)
GE   104.00 (+1.01%)
MU   74.30 (+0.35%)
AMD   105.12 (-0.97%)
T   27.17 (-0.07%)
F   13.84 (+0.95%)
ACB   6.01 (-2.28%)
DIS   175.56 (-0.39%)
PFE   43.93 (-0.59%)
BA   221.16 (+0.03%)
BAC   42.22 (+1.27%)
S&P 500   4,449.73 (+0.02%)
DOW   34,768.32 (+0.01%)
QQQ   371.17 (-0.49%)
AAPL   146.06 (-0.52%)
MSFT   297.29 (-0.76%)
FB   348.59 (+0.76%)
GOOGL   2,832.87 (+0.30%)
TSLA   761.30 (+1.02%)
AMZN   3,399.44 (-0.48%)
NVDA   218.98 (-2.60%)
BABA   146.34 (-3.21%)
NIO   35.51 (-1.39%)
CGC   13.98 (-3.98%)
GE   104.00 (+1.01%)
MU   74.30 (+0.35%)
AMD   105.12 (-0.97%)
T   27.17 (-0.07%)
F   13.84 (+0.95%)
ACB   6.01 (-2.28%)
DIS   175.56 (-0.39%)
PFE   43.93 (-0.59%)
BA   221.16 (+0.03%)
BAC   42.22 (+1.27%)
S&P 500   4,449.73 (+0.02%)
DOW   34,768.32 (+0.01%)
QQQ   371.17 (-0.49%)
AAPL   146.06 (-0.52%)
MSFT   297.29 (-0.76%)
FB   348.59 (+0.76%)
GOOGL   2,832.87 (+0.30%)
TSLA   761.30 (+1.02%)
AMZN   3,399.44 (-0.48%)
NVDA   218.98 (-2.60%)
BABA   146.34 (-3.21%)
NIO   35.51 (-1.39%)
CGC   13.98 (-3.98%)
GE   104.00 (+1.01%)
MU   74.30 (+0.35%)
AMD   105.12 (-0.97%)
T   27.17 (-0.07%)
F   13.84 (+0.95%)
ACB   6.01 (-2.28%)
DIS   175.56 (-0.39%)
PFE   43.93 (-0.59%)
BA   221.16 (+0.03%)
BAC   42.22 (+1.27%)
ASX:BNO

Bionomics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume386,458 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive BNO News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter.


About Bionomics

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Bionomics (ASX:BNO) Frequently Asked Questions

What stocks does MarketBeat like better than Bionomics?

Wall Street analysts have given Bionomics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bionomics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Bionomics' earnings last quarter?

Bionomics Limited (ASX:BNO) released its quarterly earnings data on Friday, February, 15th. The company reported ($0.02) EPS for the quarter.
View Bionomics' earnings history
.

Who are Bionomics' key executives?

Bionomics' management team includes the following people:
  • Dr. Errol B. De Souza, Exec. Chairman (Age 68, Pay $363.28k)
  • Mr. Adrian Hinton, Acting Chief Financial Officer
  • Prof. Paul Rolan, Consultant Chief Medical Officer of Clinical Neuroscience
  • Ms. Suzanne Irwin B.Com., FCIS, Company Sec.

What other stocks do shareholders of Bionomics own?

What is Bionomics' stock symbol?

Bionomics trades on the ASX under the ticker symbol "BNO."

How much money does Bionomics make?

Bionomics has a market capitalization of $0.00 and generates $928,073.00 in revenue each year.

What is Bionomics' official website?

The official website for Bionomics is www.bionomics.com.au.

Where are Bionomics' headquarters?

Bionomics is headquartered at 31 Dalgleish St, THEBARTON, SA 5031, Australia.

How can I contact Bionomics?

Bionomics' mailing address is 31 Dalgleish St, THEBARTON, SA 5031, Australia. The company can be reached via phone at +61-8-83546100.


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.